NDAs SHOULD CONTAIN NARRATIVE DESCRIPTIONS OF DEATHS AND SERIOUS ADVERSE EVENTS OCCURRING IN CLINICAL TRIALS, FDA's GUIDELINE FOR CLINICAL DATA IN AN NDA SAYS